The study published by Avadel Pharmaceuticals emphasizes the need for once-at-bedtime oxybate dosing for narcolepsy, which could lead to increased demand for their products. As the study found that decreased dosing frequency is the most important attribute for overall product choice, improving patient quality of life, and reducing anxiety, this could potentially boost Avadel's revenues and positively impact their stock price in the short term.